Hearing Economics

Downstream Consequences of Aging is a bi-monthly series written by guest columnist Barbara Weinstein, PhD.  Today’s post is especially timely, on the heels of the IOM final report and anticipating the FDA review process that generated 160 stakeholder comments.1    The focus of the public workshop hosted by the FDA on April 21, entitled “Streamlining for Good Manufacturing Practices (GMP)

“Peeling the Onion” is a monthly column by Harvey Abrams, PhD.   Before we get started, a disclaimer: This post will name names – hearing aid products, a health insurance company, and hearing health care benefit programs. I have no financial or non-financial interests in any of the products/companies mentioned except as a subscriber to the GEHA national health insurance

Since its inception, Hearing Economics has toiled persistently, if not rigorously, to infuse basic economic thinking and its lexicon into the audiology world. The goal is to broaden our view, giving us more opportunities to strengthen our grip on our profession. In that spirit, the five-post barriers series fits into the Econ 202 discourse which pops up occasionally.  Econ posts

This is the almost-final Econ 202 post on barriers that exist in the US hearing aid manufacturing and delivery system.1   Parts 1 online pharmacy https://thehatcherychicago.org/wp-content/uploads/2018/05/124.html no prescription pharmacy ,  2 and 3 addressed regulatory requirements that discourage new entrants; legal and economic definitions of barrier to industry entry/exit; structural and strategic barriers in the hearing aid industry; and specific strategic barriers used by incumbent manufacturers

Some anecdotal observations precede the current hearing aid patent list, some superficial, others not so much. Best Name for a New Entrant:  Brain Basket, LLC (Auditory Comprehension and Audibility Device, #9301066)   Who’s Got the Power   The big developing technology–accounting for over 10% of today’s list–is extended, connected, sustainable, or implantable power solutions. Big 6 and CI manufacturers own

There are no barriers that discourage new entrants to the hearing aid industry (previous post at HHTM). Part 1 online pharmacy https://tentawningclinic.co.uk/images/products/diflucan.html no prescription online pharmacy suhagra for sale no prescription pharmacy  of the barrier series itemized regulatory requirements that discourage new entrants; Part 2 distinguished between legal and economic definitions of barrier to industry entry/exit and briefly described some

“Signal & Noise” is a bimonthly column by Brian Taylor, AuD.   Profits are an essential part of a free enterprise system. They provide employees and their families with an income, give shareholders a return, foster innovation and signal where capital needs to be invested in order to improve or grow a business.   Profit Margins Reveal and Conceal  

Amidst technological disruption and social policy discussions that cast a pall over the dispensing landscape, it is surprisingly refreshing to hang out with fellow travellers.  That term, often a pejorative, best describes the relationship of Hearing Economics to the world of audiology and hearing aids: “a person who sympathizes with the beliefs of an organization or cooperates in its activities

“Peeling the Onion” is a monthly column by Harvey Abrams, PhD. online pharmacy buy fluoxetine online no prescription John’s current stop on his patient journey is the action stage – that stage of the journey when John, after contemplation and preparation, initiates change and takes action to resolve his communication problems. Recall that the Transtheoretical (changes of change) Model consists

There are no barriers that discourage new entrants to the hearing aid industry  (previous post at HHTM) Today’s Econ 202 post continues its contrarian ways by scaling barriers of varying sizes in the US hearing aid manufacturing and delivery system.   Part 1 itemized regulatory requirements for manufacturers, audiologists and providers which pose varying structural challenges to new entries, compared to incumbents.  The economic view